Yang C.-Y.CHUN-YI LUCHIN-YUN LEEPEI-LAN SHAOWang C.-Y.Wu T.-Z.LI-MIN HUANG2021-06-242021-06-2420041684-1182https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644226377&partnerID=40&md5=6be7efd06f5d5f347e332872acd96dd4https://scholars.lib.ntu.edu.tw/handle/123456789/566631The safety, tolerability and immunogenicity of inactivated hepatitis A vaccine (VAQTA, Merck and Co. Inc., West Point, PA, USA) were investigated in 28 seronegative healthy adult volunteers. The age range was 25-35 years, and the mean age was 29 years. Two doses of the vaccine, each containing 50 U of hepatitis A virus antigen, were administered into the deltoid region 24 weeks apart. No serious vaccine-related adverse reactions were reported. Four weeks after the first dose, the geometric mean titer (GMT) was 150 mlU/mL, and the seroconversion rate was 100%. Twenty eight weeks after the first dose (4 weeks following the second dose), the GMT was 4576 mIU/mL. This study demonstrated that VAQTA is safe and highly immunogenic in healthy young adults in Taiwan.[SDGs]SDG3hepatitis A antigen; hepatitis A vaccine; inactivated vaccine; adult; antibody blood level; antibody titer; article; drug dose regimen; drug efficacy; drug safety; drug screening; drug tolerability; erythema; fatigue; female; hepatitis A; Hepatitis A virus; human; human experiment; immunogenicity; injection pain; male; normal human; open study; seroconversion; Taiwan; Adult; Antibodies, Viral; Drug Tolerance; Female; Hepatitis A Vaccines; Hepatitis A virus; Humans; Male; Safety; Time Factors; Vaccines, Inactivatedjournal article153406482-s2.0-4644226377